Alistair is a seasoned pharma executive with more than 25 years of experience in the industry, across manufacturing, consultancy, business and corporate development, data management and clinical operations. Until April 2022 Alistair was CEO of leading, integrated CRO Syneos Health Inc. a role which he held for 6 years. Syneos was the result of a combination of inVentiv Health and INC Research in 2017, of which Alistair was CEO. Alistair led the merger that formed Syneos, which brought together approximately 24,000 employees serving customers in 110 countries with innovative, end-to-end solutions to accelerate their clinical development and commercialisation timelines. Prior to becoming CEO of INC Research, Alistair led multiple functions including Global Business Development and Marketing, Alliances Development and Delivery, Global Oncology, and Clinical Development Services.
Alistair has served as Chair of ACRO, the Association of Clinical Research Organisations, having been on its board for approximately seven years, and is Board Member of the Medicines Discovery Catapult.
Alistair received his Masters degree from Cranfield University, and Batchelors degree from Plymouth University.
Dr Adam M Hill
Chief Executive Officer
Adam is a dual-qualified Clinician and Mechanical Engineer with a career built at the interface of industry, academia and health systems. Over the last 2 decades he has trained in surgery in the British Army; founded a successful applied research centre at Imperial College London; provided growth strategy and investment advice to global life science companies on behalf of the British Government; led the global medical function of a multinational, publicly-listed health IT company; and pivoted a Formula One team into a developer of health technology. Currently, Adam sits on the board of the ABHI as Vice Chair, is a Visiting Professor in Global Health Innovation at Imperial College London and a Non-Executive Director of Imperial College Health Partners and MyRecovery.ai.
Adam graduated from Imperial College London as a Medical Doctor whilst also earning a PhD in Engineering, attending Imperial College Business School and the Royal Military Academy Sandhurst. He received his postgraduate clinical training from the Royal College of Surgeons of England, and professional engineering qualification from the Institution of Mechanical Engineers.
Non Executive Director
Mr Bunting joined Balderton Capital (UK) LLP as a General Partner in 2007. He was previously a partner of Goldman Sachs where he spent 18 years. At Goldman Sachs, Mr Bunting held various roles including Global Head of Equity Capital Markets (2002 to 2005) and Vice-Chairman of Goldman Sachs International (2005 to 2006).
He is also a Trustee of the Rainbow Trust Children’s Charity ; the Paul Hamlyn Foundation and the Royal Opera House. Tim is a graduate of the University of Cambridge.
Dr Annalisa Jenkins
Senior Independent Non Executive Director
Dr Annalisa Jenkins, M.B.B.S., F.R.C.P. is a biopharma thought leader with over 25 years of industry experience.
Dr Jenkins has extensive recent experience in building and financing biotech companies pursuing cures for the most challenging rare diseases to address important medical issues globally. She has consistently built and led teams advancing programs from scientific research through clinical development, regulatory approval, and into healthcare systems globally. In addition, she is an advocate for diversity and inclusion, particularly for women in science.
Dr Jenkins served as president and CEO of Dimension Therapeutics, a leading gene therapy company that she took public on the NASDAQ and subsequently sold to Ultragenyx. Prior leadership roles have included the head of global research and development and executive vice president global development and medical at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years – including serving as senior vice president and head of global medical affairs.
Earlier in her career, Dr Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander.
In addition to Oncimmune, Dr Jenkins is a board member of several growing companies, including AVROBIO, COMPASS Pathways, AOBiome, AgeX, ADOR Diagnostics, MedCity, DMNoMore, Conduit Connect, Affimed, Genomics England, Cocoon Biotech Inc. (Non-Executive Chair), and Kuur Therapeutics (Non-Executive Chair).
She also is a committee member of the Science Board to the U.S. Food & Drug Administration, which advises FDA leadership on complex scientific and technical issues, board member at Faster Cures a centre of The Milken Institute and Chair of The Court The London School of Hygiene and Tropical Medicine.
Independent Non Executive Director
Mr Unitt was Chief Financial Officer at the University of Nottingham, a major shareholder in Oncimmune, until July 2016. Prior to working in higher education at the university, he was a finance director for 20 years in a wide range of industries. His more recent background includes 11 years at Boots plc, where he was Finance Director for 4 years of Boots Healthcare International, its over the counter medicines business.
Mr Unitt has also held a number of non executive directorships in the NHS and private sector.
John qualified as a chartered accountant in London with Touche Ross in 1996, before a 25-year career in the City raising growth capital and advising small- and mid-cap companies. John initially started out in corporate finance, before moving into equity sales and corporate broking where he spent most of his career. John has helped to raise over £5bn for his clients, much of which was while he was Chief Executive of Zeus Capital for over ten years. John has recently become Chief Executive Officer of Kelso Group Holdings plc, which is listed on the Main Market Standard Segment of the London Stock Exchange.